Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript

We learned this from our lymphoma studies and from our other studies, preclinical studies. So, we’re going to be able to determine very early in the study about safety. We already know that from our lymphoma studies we’ll be able to determine whether or not we’re having the immunologic effects that we expect and, of course, we’ll be monitoring the clinical efficacy. Now, the immunologic effects are important because this becomes the entry point, the stepping stone to other immune diseases. What are the other immune diseases? Asthma is one that would be — is very much Th2, psoriasis, scleroderma, several other diseases. We have a whole list of them on our website presentation. So, this is a very important study in that we get data quickly and it’s very informative, not only for the purpose of atopic dermatitis, but it opens up the whole field.

We — basically, this study puts ITK inhibition on the map as an important therapeutic modality for a host of immune diseases. It’s very reminiscent of an antibody that I worked on called Rituxan and — where we — what we learned in lymphoma taught us about what happens to B cells, et cetera and that opened the door for a lot of other dermatologic and immunologic diseases. So, that was a long way to answer your question, but I wanted to make sure that we really had a proper perspective. I appreciate the question.

Rosemary Li: Thank you so much.

Operator: Thank you. And there are no further questions at this time. I’ll turn the floor back to Richard Miller for closing remarks.

Richard Miller: Thank you, operator. Well, I want to thank everyone for participating in the call today. We look forward to giving additional updates each quarter and advancing soquelitinib and other products in the coming months. Thank you very much.

Operator: Thank you. This concludes today’s call. All parties may disconnect. Have a good day.